The drug is pulmonary surfactant, a soap-like substance administered directly into the lungs of premature babies who cannot yet produce enough of it on their own. Since its introduction into clinical practice in the early 1990s, surfactant replacement therapy has cut mortality from Respiratory Distress Syndrome by approximately 50 percent and pushed survival rates for extremely premature infants weighing under 1,500 grams from roughly 5 percent in the 1960s to upwards of 90 percent today. Few medical interventions in the past half-century can claim such a dramatic reversal of fortune for such vulnerable patients.
For readers of a brain health and dementia care site, the relevance runs deeper than it might first appear. Premature birth and the oxygen deprivation that accompanies severe lung failure are well-established risk factors for neurodevelopmental injury. Every premature infant whose lungs are stabilized by surfactant is an infant whose developing brain is spared prolonged hypoxia — the kind of insult that can set the stage for cognitive difficulties years or even decades later. This article traces the science behind surfactant, the researchers who discovered its role, the FDA-approved drugs now in use, the global gaps in access that still cost lives, and the newer developments in 2025 and 2026 that are pushing neonatal care further forward.
Table of Contents
- What Is the Drug Given to Premature Babies’ Lungs, and How Does It Save Lives?
- The Groundbreaking Discovery That Changed Neonatal Medicine Forever
- FDA-Approved Surfactant Drugs and How They Compare
- Why Brain Health Depends on What Happens in the First Hours of Life
- The Global Access Gap That Still Costs Thousands of Lives
- New Delivery Methods Are Making Surfactant Safer to Administer
- What the Next Generation of Surfactant Research Could Mean
- Conclusion
- Frequently Asked Questions
What Is the Drug Given to Premature Babies’ Lungs, and How Does It Save Lives?
Pulmonary surfactant is composed of roughly 80 percent phospholipids, 5 to 10 percent cholesterol, and about 10 percent surfactant-associated proteins. In a healthy, full-term newborn, this mixture coats the alveoli — the tiny air sacs where oxygen crosses into the bloodstream — and reduces surface tension so the lungs don’t collapse each time the baby exhales. Premature babies born before 32 weeks of gestation simply haven’t had enough time to produce adequate surfactant, which is why they develop Respiratory Distress Syndrome at staggering rates. At 24 weeks gestation, the incidence of RDS is 98 percent. By 34 weeks, it drops to 5 percent. By 37 weeks, it falls below 1 percent. RDS affects about 1 percent of all newborns overall, which translates to roughly 24,000 infants born each year in the United States alone, with approximately 860 deaths annually. What makes surfactant replacement therapy so remarkable is its directness: the drug is delivered straight into the baby’s airway, where it immediately begins doing the job the infant’s own lungs cannot yet manage.
The effect is often visible within minutes on a ventilator readout — oxygen requirements drop, lung compliance improves, and the infant stabilizes. It is not a cure in the traditional sense. It is a bridge, buying the baby’s lungs the time they need to mature and begin producing surfactant on their own. However, surfactant therapy is not without limitations. It does not work equally well for every infant, and some babies require multiple doses. Extremely premature infants may develop bronchopulmonary dysplasia even after successful surfactant administration, and the therapy addresses only the surfactant deficiency — not the dozens of other complications that accompany extreme prematurity, from intraventricular hemorrhage to necrotizing enterocolitis. The drug saves lungs. It does not, by itself, save everything.
The Groundbreaking Discovery That Changed Neonatal Medicine Forever
The story of surfactant therapy begins in 1959 at Harvard medical School, where Dr. Mary Ellen Avery and Dr. Jere Mead published a finding that would eventually reshape neonatal intensive care worldwide. They demonstrated that premature infants who died of what was then called “hyaline membrane disease” were deficient in lung surfactant. By comparing lung extracts from affected infants with those from healthy ones, they found markedly higher surface tension in the diseased lungs. The implication was clear: these babies were not dying from infection or structural defects. They were dying because their lungs lacked a specific chemical substance.
Their research built on earlier work by Von Neergaard and Pattle, who had identified surface-tension-reducing activity in mammalian alveoli, but Avery and Mead made the crucial clinical connection. What followed, however, was a frustratingly long gap. Between 1968 and 1980, no clinical trials of surfactant replacement were conducted in human infants, even as extensive animal studies accumulated evidence that the approach could work. The medical community was cautious, and the technology for delivering a lipid-protein mixture into a premature infant’s fragile airways had not yet caught up to the science. The breakthrough came in 1980, when Dr. Tetsuro Fujiwara at Akita University in Japan conducted the first successful clinical trial of surfactant replacement in 10 preterm infants, published in The Lancet. His formulation — a modified bovine lung extract called Surfactant-TA, later branded as Surfacten — was created through organic solvent extraction supplemented with palmitic acid. Fujiwara’s trial proved the concept was viable in human newborns and set in motion the series of larger trials that would lead to FDA approval a decade later.
